Canaan

Transposon?Therapeutics has expanded its development pipeline into #oncology with the acquisition of a portfolio of novel #nucleoside?#chemotherapeutics from PrimeFour Therapeutics.? The transaction helps build upon Transposon's leadership position in developing best-in-class, late-stage nucleoside reverse transcriptase inhibitors for #neurodegenerative and #autoimmune diseases such as #ALS?#PSP?#Alzheimer’s. Read the company’s press release here:?https://lnkd.in/e7BCYWXF

We are happy to spread word of?Pathios Therapeutics becoming a clinical-stage company. This morning, the company announced that the first patient was dosed in a Phase 1/2 clinical trial of its lead development candidate, PTT-4256. The compound is a first-in-class, potent and selective inhibitor of GPR65, an acid sensing a G protein-coupled receptor. PTT-4256 leverages a unique therapeutic strategy in the fight against solid tumors by working to counteract the #immunosuppressive polarization of #immune cells in the #tumor #microenvironment. Preclinical studies have demonstrated promising anti-tumor activity and we are excited to see what plays out in the clinic. Read more details in the press release here: https://lnkd.in/ewmUvq9a

Congratulations to the team at?Nocion Therapeutics, Inc. for kicking off a Phase 2b clinical trial of its lead development candidate, taplucanium.?The ASPIRE study is a global, multi-center trial evaluating the efficacy, safety and tolerability of Taplucanium #Inhalation Powder (NOC-110) for the treatment of chronic #cough. Canaan's?Julie Grant sits on the?Nocion?board.? ? Read the company's announcement on the news here:?https://lnkd.in/ehk8FE4T

We’re thrilled and honored to share that Alkymi has been selected as one of the ‘100 Most Innovative Fintech Startups’ by CB Insights! Being recognized in CB Insights’ 2024 Fintech 100 is an exciting milestone for our company, indicative of the value realized by our customers and the hard work of our team to bring AI-powered data automation to private markets firms globally. This builds on a big year for Alkymi, which has included adding industry-leading firms like Northwestern Mutual to our customer list, expanding our partnership with SimCorp, and forming a strategic partnership with Lionpoint Group (an Alpha Group company). Read more in our press release: https://lnkd.in/gTwTHZUs #Fintech100

Congratulations Savvy! https://lnkd.in/gAyA4fgB

Big happenings at?Glooko with the appointment of?Mike Alvarez as new CEO and the closing of a $100M Series F round of financing.?As the company said in its press release, Mike's appointment and the new capital will allow Glooko to accelerate global product expansion of its cutting-edge #digital #healthcare platform and life sciences work. This is not just a big win for Glooko but for all people with #diabetes, who can utilize the Glooko platform to better manage their condition and strengthen engagement with, and care from, their #healthcare team. Canaan is proud to be a long-time investor in this great company. Congrats to the entire Glooko team, including our own Wende Hutton who sits on the?company's?board.? ? https://lnkd.in/ewqqVYiP

We are looking forward to the?oral and poster presentations from Transposon?Therapeutics at the upcoming 2024 Annual Northeast ALS Consortium (NEALS) Meeting. The company will share the promising results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (#ALS) and/or frontotemporal dementia (#FTD) related to hexanucleotide repeat expansion in the C9orf72 gene. Data highlights will include TPN-101's lowering effects on key disease #biomarkers, as well as clinical benefits on the Revised ALS Functional Rating Scale and Vital Capacity. #ALS #PSP #Alzheimer’s. Read the company’s press release here: https://lnkd.in/eUyh6Vh5

This week, Manoj and I hosted an awesome group of founding engineers, PMs, and builders for dinner in SF. We had folks join from leading AI and infra startups like Contextual AI, Gradient, Fireworks AI, DatologyAI, Predibase, and more. We heard some hot takes on AI related to finetuning, research reproducibility, synthetic data limitations, and a few more that will stay behind closed doors (: Canaan and Menlo Ventures are excited to host more events like this in SF and NY! If you're working on infrastructure or AI startups, we'd love to have you at the next one. DMs are open! thanks for joining — Andrew, Sujay, Michael, Eva, Max, Raymond, Abhay, Ning, Bihan, Samarth, Shreyas

The Canaan portfolio has added new talent.?Halda Therapeutics has announced the appointment of?Chris Schade as president and CEO.?Chris brings the company proven leadership and an impressive track record of company building, which is timely as Halda is poised to evolve into a clinical-stage #cancer company.?Canaan's own?Tim Shannon will continue to serve as the company’s chairman of the board. https://lnkd.in/e6EeQZGk

We're excited to announce our $8M Pre-Series A priced round led by Canaan, bringing total investment to $11M to date. Press release: https://lnkd.in/gjE8AjWj In addition to Canaan, Correlation Ventures, Higher Life Ventures, Ajinomoto Co., Inc., Automotive Ventures, Outpost Ventures, Potomac Angel Capital, and MaC Venture Capital participated in the round.